Dr Tami Rashal

Dr. Tami Rashal is a board-certified hemato-oncologist and a driving force in medical and regulatory strategy.

Her expertise is underscored by her direct leadership in three NDA submissions achieving regulatory approvals at Karyopharm Therapeutics Inc. Dr. Rashal has also spearheaded early-stage development, directing multiple IND submissions and strategically overseeing pre-IND efforts at BiVictriX Therapeutics plc, Karyopharm Therapeutics Inc. (Xpovio®, IL-12 programs), and Sporos BioVentures.

Her ability to craft compelling regulatory plans and design robust clinical protocols is evident throughout her extensive experience in guiding drug development programs.

As CMO at SBH Sciences Inc., she leverages this deep strategic acumen to translate promising research into viable clinical assets.